(Q34608817)

3 August 2017

1 reference

title

Hypertension and fatty liver: guilty by association? (English)

1 reference

3 August 2017

Brookes MJ

1

1 reference

3 August 2017

Cooper BT

series ordinal

2

1 reference

3 August 2017

publication date

1 February 2007

1 reference

Journal of Human Hypertension

3 August 2017

published in

1 reference

3 August 2017

volume

21

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

264-270

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1002148

3 August 2017

exact match

0 references

cites work

Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Nonalcoholic fatty liver disease: an agenda for clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Clinical features and natural history of nonalcoholic steatosis syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Nonalcoholic steatohepatitis: a study of 49 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Insulin resistance is a characteristic feature of primary hypertension independent of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Trends and correlates of class 3 obesity in the United States from 1990 through 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Lifetime Health and Economic Consequences of Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Epidemiology of the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Liver dysfunction in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Gamma-glutamyltransferase, alcohol, and blood pressure. A four year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Gamma-glutamyltransferase: an effect modifier in the association between age and hypertension in a 4-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Association of nonalcoholic fatty liver disease with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Insulin resistance in obesity: metabolic mechanisms and measurement methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Serum leptin levels in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Fatty infiltration of liver in hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Nonalcoholic Steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Body fat topography as an independent predictor of fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Adiponectin and its receptors in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Hepatotoxicity associated with carvedilol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Labetalol hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

Prevalence of and risk factors for hepatic steatosis in Northern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Insulin resistance in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

The Tromsø Study. Distribution and population determinants of gamma-glutamyltransferase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Alcohol, high blood pressure, and serum gamma-glutamyl transpeptidase level

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

The relationship between serum gamma-glutamyl transpeptidase levels and hypertension: common in drinkers and nondrinkers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Liver function tests in diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Nonalcoholic steatohepatitis: An expanded clinical entity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

PPARs: transcription factors controlling lipid and lipoprotein metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Diagnostic value of platelet derived growth factor-BB, transforming growth factor-β1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Paradoxical lack of ultrasound attenuation with gross fatty change in the liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002148

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1002148

1 reference

Dimensions Publication ID

3 August 2017

1012556680

0 references

1 reference